Except for OI and osteoporosis, the clinical data supporting bisphosphonate use in metabolic bone disease in children are sparse and largely anecdotal. Currently, physicians prescribe these drugs for compassionate use in conditions deemed otherwise medically untreatable. Several controversial issues, such as effects on osteotomy healing, statural growth, and risk factors for osteonecrosis of the jaw, remain to be addressed. Additional well-designed studies are needed to establish or refute the utility of bisphosphonates in other clinical pediatric conditions.
|Original language||English (US)|
|Number of pages||7|
|Journal||Journal of the American Academy of Orthopaedic Surgeons|
|State||Published - Jan 1 2006|
ASJC Scopus subject areas
- Orthopedics and Sports Medicine